Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

Tesamorelin_10MG

Tesamorelin

Tesamorelin is a synthetic peptide analog of growth hormone–releasing hormone (GHRH 1–44), structurally engineered to enhance stability and resistance to enzymatic degradation compared to native GHRH. In scientific research, Tesamorelin is utilized as a peptide research tool for investigating hypothalamic–pituitary signaling, peptide–receptor interactions, and regulated hormone release mechanisms in controlled experimental models.*

Due to its stabilized sequence and extended biological half-life relative to endogenous GHRH, Tesamorelin is frequently referenced in endocrinology, peptide pharmacology, and molecular signaling research as a reproducible compound for studying GHRH receptor activation and downstream intracellular signaling pathways.*

  • Peptide Name: Tesamorelin
  • Peptide Class: Synthetic growth hormone–releasing hormone (GHRH) analog
  • Amino Acid Length: 44 amino acids
  • Form: Lyophilized powder
  • Purity: ≥99% (HPLC verified)
  • Quantity: 10 mg per vial
  • Molecular Formula: C₂₂₁H₃₄₂N₆₂O₆₇
  • Molecular Weight: 5135.9 g/mol
  • CAS Number: 218949-48-5
  • Analytical Verification: HPLC and Mass Spectrometry (MS)
  • Manufacturing: Solid-phase peptide synthesis with in-house purification
  • Designation: For Research Use Only (RUO)

$76.00

$72.20 each
$68.40 each

Products will arrive in a lyophilized (powder) form for maximum stability.

Free domestic shipping on orders over $300

Tesamorelin

Scientific & Research Context

Tesamorelin has been examined in published research for its role in GHRH-mediated signaling pathways, including experimental studies evaluating peptide–receptor binding, second messenger activation, and regulated hormone secretion in in-vitro and preclinical models.* Research applications have also explored Tesamorelin as a tool for studying endocrine feedback mechanisms, peptide stability optimization, and structure–function relationships of GHRH analogs without direct endocrine replacement.*

In laboratory research environments, Tesamorelin has been utilized to investigate:*

  • GHRH receptor signaling and downstream intracellular pathways*
  • Hypothalamic–pituitary axis regulation models*
  • Peptide stability and enzymatic resistance mechanisms*
  • Structure–activity relationships of GHRH-derived peptides*
  • Hormone release dynamics in controlled experimental systems*

Its defined amino acid sequence, enhanced stability profile, and well-characterized molecular properties make Tesamorelin a valuable compound for peptide chemistry, endocrinology research, and molecular signaling studies.*

Quality & Analytical Assurance

Each batch of Tesamorelin undergoes rigorous analytical testing to confirm molecular identity, sequence accuracy, and purity. Verification through validated High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) methodologies ensures batch-to-batch consistency, reliability, and reproducibility across research applications.

All synthesis, purification, and quality testing are performed under strict internal quality control standards to ensure research-grade integrity.

Storage & Handling

Tesamorelin is supplied in lyophilized form to enhance stability during storage and shipping. Store unopened vials in a cool, dry environment protected from light. Reconstitution and handling should follow established peptide research and laboratory best practices to preserve molecular integrity and minimize degradation. Avoid repeated freeze–thaw cycles.

For further information on proper storage techniques, click the button…

Storage Instructions

Referenced Scientific Literature
Provided for informational and educational purposes only

  • Falutz J, et al. Effects of tesamorelin, a growth hormone–releasing factor analogue, on visceral fat in HIV-infected patients with abdominal fat accumulation. Journal of Clinical Endocrinology & Metabolism, 2007; 92(11): 4291–4298.
  • Falutz J, et al. Metabolic effects of a growth hormone–releasing factor in patients with HIV. New England Journal of Medicine, 2007; 357(23): 2359–2370.
  • Stanley TL, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases, 2012; 54(11): 1642–1651.
  • Stanley TL, et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. AIDS, 2012; 26(16): 2075–2084.
  • Grinspoon S, et al. Long-term safety and efficacy of tesamorelin in HIV-infected patients with excess abdominal fat. Journal of Acquired Immune Deficiency Syndromes, 2012; 61(3): 339–345.
  • Mangili A, Falutz J, Mamputu J-C, Stepanians M, Hayward B. Predictors of treatment response to tesamorelin, a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat. PLOS One, 2015; 10(10): e0140358.
  • Clinical Review Report: Tesamorelin (Egrifta). Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, 2016.
  • Rochira V, Guaraldi G. Growth hormone deficiency and human immunodeficiency virus. Best Practice & Research Clinical Endocrinology & Metabolism, 2017; 31(1): 91–111.
  • Thompson M, et al. Tesamorelin improves lipid profile and reduces inflammatory markers in patients with HIV-associated lipodystrophy. AIDS, 2013; 27(4): 513–522.
  • Koutkia P, et al. Effects of growth hormone–releasing hormone on body composition and metabolic parameters in patients with HIV-associated lipodystrophy. Journal of Clinical Endocrinology & Metabolism, 2004; 89(11): 629–635.
  • Stanley TL, Grinspoon SK. Body composition and metabolic changes associated with growth hormone–releasing hormone analog therapy. Endocrine Reviews, 2015; 36(1): 15–31.
  • Mulligan K, et al. Growth hormone–releasing hormone analog therapy and its effects on insulin-like growth factor-1 and metabolic signaling. Clinical Endocrinology, 2006; 64(2): 186–193.
  • Johannsson G, et al. Growth hormone–releasing hormone analogs: pharmacology and clinical implications. European Journal of Endocrinology, 1999; 141(1): 1–14.
  • Vance ML, et al. Growth hormone–releasing hormone and regulation of pituitary growth hormone secretion. Endocrinology and Metabolism Clinics of North America, 1992; 21(3): 545–563.
  • Biller BMK, et al. Mechanisms of growth hormone release and the role of GHRH analogs in endocrine research. Endocrine Practice, 2010; 16(4): 712–720.
  • Tuffaha SH, et al. Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury. Expert Opinion on Therapeutic Targets, 2016; 20(10): 1259–1265.
  • Friedman SD, et al. Growth hormone–releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurology, 2013; 70(7): 883–890.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.